The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

IODINE-131     molecular iodine

Synonyms: Iodine 131, Iodine I 131, I-131, AC1L2NQ2, I 131, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of molecular iodine


Psychiatry related information on molecular iodine


High impact information on molecular iodine


Chemical compound and disease context of molecular iodine


Biological context of molecular iodine

  • A phase I trial was conducted in which a uniform quantity of antibody labeled with escalating doses of iodine 131 (131I) was administered to patients with advanced gastrointestinal (GI) malignancies to evaluate tolerance and pharmacokinetics [17].
  • PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine-131 ((131)I)-labeled 81C6 antitenascin monoclonal antibody (mAb) administered clinically into surgically created resection cavities (SCRCs) in malignant glioma patients and to identify any objective responses with this treatment [18].
  • Renal plasma flow was computed from iodine 131 (I-131 Hippuran; Mediphysics, Paramus, NJ) orthoiodohippurate, excretion curves, and glomerular filtration rate (GFR) was determined by creatinine clearance [19].
  • Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway [15].
  • The kinetics, dosimetry, and response of iodine-131 alpha-amino-(4-hydroxybenzylidene)-diphosphonate ([131I]BDP3) treatment were investigated with patients who had pain symptoms from bone metastases of various primary carcinoma [20].

Anatomical context of molecular iodine


Associations of molecular iodine with other chemical compounds


Gene context of molecular iodine


Analytical, diagnostic and therapeutic context of molecular iodine


  1. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.G., Blomgren, H., Taube, A. N. Engl. J. Med. (1992) [Pubmed]
  2. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Badger, C.C., Nelp, W.B., Glenn, S., Butchko, G., Fisher, D., Porter, B. N. Engl. J. Med. (1993) [Pubmed]
  3. Myocardial infarct imaging of antibodies to canine cardiac myosin with indium-111-diethylenetriamine pentaacetic acid. Khaw, B.A., Fallon, F.T., Strauss, H.W., Haber, E. Science (1980) [Pubmed]
  4. Iodine 131 uptake by primary lung adenocarcinoma. Misinterpretation of 131I scan. Fernandez-Ulloa, M., Maxon, H.R., Mehta, S., Sholiton, L.J. JAMA (1976) [Pubmed]
  5. Emotional stress and iodine-131 therapy for Grave's disease. Feigenson, F. J. Nucl. Med. (1985) [Pubmed]
  6. Micronucleus formation in lymphocytes of children from the vicinity of Chernobyl after (131)I therapy. Müller, W.U., Dietl, S., Wuttke, K., Reiners, C., Biko, J., Demidchik, E., Streffer, C. Radiation and environmental biophysics. (2004) [Pubmed]
  7. Perspective: National Cancer Institute summary report about estimated exposures and thyroid doses received from iodine 131 in fallout after Nevada atmospheric nuclear bomb tests. Hundahl, S.A. CA: a cancer journal for clinicians. (1998) [Pubmed]
  8. Reactor accidents. Public health strategies and their medical implications. Becker, D.V. JAMA (1987) [Pubmed]
  9. The role of radioimmunodetection in the management of testicular cancer. Javadpour, N., Kim, E.E., DeLand, F.H., Salyer, J.R., Shah, U., Goldenberg, D.M. JAMA (1981) [Pubmed]
  10. Thyroid cancer after diagnostic doses of iodine-131: a retrospective cohort study. Holm, L.E., Wiklund, K.E., Lundell, G.E., Bergman, N.A., Bjelkengren, G., Cederquist, E.S., Ericsson, U.B., Larsson, L.G., Lidberg, M.E., Lindberg, R.S. J. Natl. Cancer Inst. (1988) [Pubmed]
  11. N-nitroso-N-methylurea-induced mammary carcinogenesis: effect of prolactin on expression of Ia antigen by tumor cells. Bernard, D.J., Maurizis, J.C., Chassagne, J., Chollet, P., Plagne, R. J. Natl. Cancer Inst. (1986) [Pubmed]
  12. Uptake of Technetium pertechnetate in a parathyroid adenoma presenting as an Iodine-131 "cold" nodule. Alagumalai, K., Avramides, A., Carter, A.C., Solomon, N.A. Ann. Intern. Med. (1979) [Pubmed]
  13. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma. Klein, J.L., Nguyen, T.H., Laroque, P., Kopher, K.A., Williams, J.R., Wessels, B.W., Dillehay, L.E., Frincke, J., Order, S.E., Leichner, P.K. Cancer Res. (1989) [Pubmed]
  14. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. Vose, J.M., Bierman, P.J., Enke, C., Hankins, J., Bociek, G., Lynch, J.C., Armitage, J.O. J. Clin. Oncol. (2005) [Pubmed]
  15. Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. Shrivastava, A., Tiwari, M., Sinha, R.A., Kumar, A., Balapure, A.K., Bajpai, V.K., Sharma, R., Mitra, K., Tandon, A., Godbole, M.M. J. Biol. Chem. (2006) [Pubmed]
  16. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. Unal, S., Menda, Y., Adalet, I., Boztepe, H., Ozbey, N., Alagöl, F., Cantez, S. J. Nucl. Med. (1998) [Pubmed]
  17. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. Yu, B., Carrasquillo, J., Milenic, D., Chung, Y., Perentesis, P., Feuerestein, I., Eggensperger, D., Qi, C.F., Paik, C., Reynolds, J., Grem, J., Curt, G., Siler, K., Schlom, J., Allegra, C. J. Clin. Oncol. (1996) [Pubmed]
  18. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Cokgor, I., Akabani, G., Kuan, C.T., Friedman, H.S., Friedman, A.H., Coleman, R.E., McLendon, R.E., Bigner, S.H., Zhao, X.G., Garcia-Turner, A.M., Pegram, C.N., Wikstrand, C.J., Shafman, T.D., Herndon, J.E., Provenzale, J.M., Zalutsky, M.R., Bigner, D.D. J. Clin. Oncol. (2000) [Pubmed]
  19. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. Shalmi, C.L., Dutcher, J.P., Feinfeld, D.A., Chun, K.J., Saleemi, K.R., Freeman, L.M., Lynn, R.I., Wiernik, P.H. J. Clin. Oncol. (1990) [Pubmed]
  20. Iodine-131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. Eisenhut, M., Berberich, R., Kimmig, B., Oberhausen, E. J. Nucl. Med. (1986) [Pubmed]
  21. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. DeNardo, G.L., DeNardo, S.J., Goldstein, D.S., Kroger, L.A., Lamborn, K.R., Levy, N.B., McGahan, J.P., Salako, Q., Shen, S., Lewis, J.P. J. Clin. Oncol. (1998) [Pubmed]
  22. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. Scheinberg, D.A., Lovett, D., Divgi, C.R., Graham, M.C., Berman, E., Pentlow, K., Feirt, N., Finn, R.D., Clarkson, B.D., Gee, T.S. J. Clin. Oncol. (1991) [Pubmed]
  23. Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging. Mulshine, J.L., Keenan, A.M., Carrasquillo, J.A., Walsh, T., Linnoila, R.I., Holton, O.D., Harwell, J., Larson, S.M., Bunn, P.A., Weinstein, J.N. Cancer Res. (1987) [Pubmed]
  24. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. Liu, S.Y., Eary, J.F., Petersdorf, S.H., Martin, P.J., Maloney, D.G., Appelbaum, F.R., Matthews, D.C., Bush, S.A., Durack, L.D., Fisher, D.R., Gooley, T.A., Bernstein, I.D., Press, O.W. J. Clin. Oncol. (1998) [Pubmed]
  25. Immunosuppressive effects of (131)I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models. Ruffner, K.L., Martin, P.J., Hussell, S., Nourigat, C., Fisher, D.R., Bernstein, I.D., Matthews, D.C. Cancer Res. (2001) [Pubmed]
  26. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. Kushner, B.H., Yeung, H.W., Larson, S.M., Kramer, K., Cheung, N.K. J. Clin. Oncol. (2001) [Pubmed]
  27. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Ashcraft, M.W., Van Herle, A.J. Am. J. Med. (1981) [Pubmed]
  28. Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. Nemecek, E.R., Hamlin, D.K., Fisher, D.R., Krohn, K.A., Pagel, J.M., Appelbaum, F.R., Press, O.W., Matthews, D.C. Clin. Cancer Res. (2005) [Pubmed]
  29. Microcirculatory obstruction in focal cerebral ischemia: albumin and erythrocyte transit. Little, J.R., Cook, A., Cook, S.A., MacIntyre, W.J. Stroke (1981) [Pubmed]
  30. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. Hooft, L., Hoekstra, O.S., Devillé, W., Lips, P., Teule, G.J., Boers, M., van Tulder, M.W. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  31. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. Juweid, M., Swayne, L.C., Sharkey, R.M., Dunn, R., Rubin, A.D., Herskovic, T., Goldenberg, D.M. Gynecol. Oncol. (1997) [Pubmed]
  32. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Vervoordeldonk, S.F., Merle, P.A., van Leeuwen, E.F., von dem Borne, A.E., Slaper-Cortenbach, I.C. Cancer (1994) [Pubmed]
  33. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Chiovato, L., Latrofa, F., Braverman, L.E., Pacini, F., Capezzone, M., Masserini, L., Grasso, L., Pinchera, A. Ann. Intern. Med. (2003) [Pubmed]
  34. Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. Goldenberg, D.M., Sharkey, R.M., Ford, E. J. Nucl. Med. (1987) [Pubmed]
  35. Synthesis of 131I-labeled glucose-conjugated inhibitors of O6-methylguanine-DNA methyltransferase (MGMT) and comparison with nonconjugated inhibitors as potential tools for in vivo MGMT imaging. Mühlhausen, U., Schirrmacher, R., Piel, M., Lecher, B., Briegert, M., Piee-Staffa, A., Kaina, B., Rösch, F. J. Med. Chem. (2006) [Pubmed]
  36. Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study. Holm, L.E., Dahlqvist, I., Israelsson, A., Lundell, G. N. Engl. J. Med. (1980) [Pubmed]
  37. Clinical radioimmunodetection of cancer with radioactive antibodies to human chorionic gonadotropin. Goldenberg, D.M., Kim, E.E., DeLand, F.H., van Nagell, J.R., Javadpour, N. Science (1980) [Pubmed]
  38. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. Cheung, N.K., Landmeier, B., Neely, J., Nelson, A.D., Abramowsky, C., Ellery, S., Adams, R.B., Miraldi, F. J. Natl. Cancer Inst. (1986) [Pubmed]
  39. Serum thyroglobulin in thyroid cancer. Black, E.G., Cassoni, A., Gimlette, T.M., Harmer, C.L., Maisey, M.N., Oates, G.D., Hoffenberg, R. Lancet (1981) [Pubmed]
  40. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. Chen, S., Yu, L., Jiang, C., Zhao, Y., Sun, D., Li, S., Liao, G., Chen, Y., Fu, Q., Tao, Q., Ye, D., Hu, P., Khawli, L.A., Taylor, C.R., Epstein, A.L., Ju, D.W. J. Clin. Oncol. (2005) [Pubmed]
WikiGenes - Universities